Breaks Categories: News

ThursdayAug 09, 2018 9:27 am

CBDNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Inks LOI with Pharmaflorx for the Supply of Cannabis Oils and Isolates

Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that it has signed a Letter of Intent (“LOI”) with Pharmaflorx Ltd. ("PFX") for the supply of cannabis oils and isolates. PFX is a privately-held late-stage Access to Cannabis for Medical Purposes Regulations ("ACMPR") applicant located in Gatineau, Quebec. Per the update, Pivot will acquire a minimum of 1,000 kg/year of cannabis oils or isolates from PFX to manufacture its patented portfolio of biocannabis products. Pivot intends to supply both the Canadian and European Union markets with its suite of patented products following receipt of fitting licenses where regulations…

Continue Reading

WednesdayAug 08, 2018 2:39 pm

CBDNewsBreaks – Canopy Rivers Corp. Upsizes Private Placement Offering

Canopy Rivers recently announced that it has amended the terms of its best efforts private placement of subscription receipts in connection with the proposed business combination transaction involving AIM2 Ventures Inc. ("AIM2"). The business transaction is intended to result in a reverse take-over of AIM2 by Canopy Rivers. Per the revised terms of the offering, the company offered to issue and sell subscription receipts at a price of $3.50 each for total gross proceeds of up to $104,125,000. The securities have not been and will not be offered or sold within the United States. To view the full press release,…

Continue Reading

WednesdayAug 08, 2018 10:55 am

CBDNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Unveils Medicinal Cannabis Division’s First Product Development Program

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced the first product development program of the company’s newly created medicinal cannabis division, which will focus on the development of cannabinoids as a preventative treatment for anxiety disorders using PreveCeutical’s proprietary Sol-gel delivery platform. Per the update, the goal of the medical cannabis division’s program is to “create an effective therapy for anxiety that can be administered subtly and infrequently, addressing concerns of currently available treatments for anxiety disorders.” According to data from the Mayo Clinic, common approaches to treating anxiety, such as the prescription…

Continue Reading

WednesdayAug 08, 2018 10:36 am

CBDNewsBreaks – SinglePoint, Inc. (SING) Issues Company Update

SinglePoint (OTCQB: SING) today provided a company update highlighting the company’s increased revenue, recent acquisitions and Form 10 filing with the Securities and Exchange Commission (“SEC”). Throughout the past year, the company has successfully integrated its acquisitions, which has been attributed as a key factor to the company’s increased revenues. For the first quarter of 2018, SinglePoint reported revenues of over $188,000, representing a significant increase compared to the same period of 2017. The company believes that the transparency and credibility provided by its recently filed Form 10-12G will also result in future growth. “We built a solid base throughout…

Continue Reading

WednesdayAug 08, 2018 9:51 am

CBDNewsBreaks – FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) Advances $1M Capital Tranche to ezGreen Compliance

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF), a royalty company for the U.S. licensed medical cannabis industry, this morning announced that it has advanced $1 million to its investee company, ezGreen Compliance, which offers a state-of-the-art enterprise compliance and point-of-sale software solution for licensed medical cannabis dispensaries and cultivators. Per the update, FinCanna has now advanced $1.75 million of the $3 million to be funded under the royalty agreement, which entitles FinCanna to a perpetual royalty equal to 10 percent of consolidated gross revenues of ezGreen, subject to certain buy-back options. “The ezGreen team is committed to creating state of…

Continue Reading

WednesdayAug 08, 2018 9:34 am

CBDNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Enters Binding LOI with HOPE Cannabis Products

Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that its wholly-owned subsidiary, Pivot Naturals LLC, has entered into a binding Letter of Intent (“LOI”) with Healthcare Options for Patients Enterprises LLC, dba HOPE Cannabis Products ("HOPE"). HOPE is fully licensed to manufacture, distribute and sell cannabis products in Nevada, offering products such as effect-based vape cartridges, syringes, micro-dosed oral sprays, pre-rolls, infused pre-rolls, infused cold brew coffee and infused lemonade. Per the LOI, HOPE will manufacture and distribute Pivot Naturals' product line in Nevada and Pivot will manufacture and distribute HOPE's product line in California. Definitive agreements,…

Continue Reading

TuesdayAug 07, 2018 3:27 pm

CBDNewsBreaks – The Flowr Corp.’s Chairman and Chief Strategist Discusses Company Activities and Outlook in Kahner Global Interview

Steve Klein, the chairman and chief strategist of The Flowr Corp., provided an overview of the company's activities and outlook during an interview that was posted on Kahner Global's website. Flowr is a Canadian licensed producer that focuses primarily on premium flower production. "On the financial side, we're working to complete a process that will lead to us being listed on the TSX Ventures exchange. That should be done by September. On the operating side, we're completing the build out of Kelowna this year, including the Hawthorne research center.  It's about 20% operational now but we need to finish it…

Continue Reading

TuesdayAug 07, 2018 3:16 pm

CBDNewsBreaks – Canopy Rivers Corp. Files Early Warning Report Regarding the Close of James E. Wagner Qualifying Transaction

Canopy Rivers announced in a recent news release that it has filed an early warning report in connection with the closing of the qualifying transaction of James E. Wagner Cultivation ("JWC"), formerly AIM1 Ventures, under National Instrument 62-103. Per the transaction, the company received 12,513,041 common shares of JWC and 2,347,826 warrants to purchase common share of JWC. Canopy Rivers did not hold any common shares or convertible securities of JWC prior to this transaction. Certain common shares held by Canopy Rivers are subject to regulatory escrow provisions. At the time of the company’s news release, Canopy Rivers reported that…

Continue Reading

TuesdayAug 07, 2018 11:05 am

CBDNewsBreaks – NUGL Inc. (NUGL) Expands Revolutionary Cannabis Platform

NUGL Inc. (OTC: NUGL) this morning posted an update regarding its marketing strategy, specifically, the expansion of its cannabis platform to the entire north american market. Through its innovative platform, the company delivers exclusive profiles and features for brands and listings in the cannabis space. NUGL’s search app enables cannabis companies and service providers to create profiles for marketing, connecting and expanding client bases in and out of the NUGL community. The software’s rating platform also delivers vital feedback to shops and professional services. “Our biggest challenge is informing and educating the community on the wide breadth of features we…

Continue Reading

TuesdayAug 07, 2018 10:21 am

CBDNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Successful Delivery of Nicotine Within Minutes in Edible Nicotine Study

Drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning announced that within minutes after dosing in an animal in vivo study, it has successfully delivered nicotine in an edible form into blood plasma. Per the update, Lexaria's DehydraTECH™ technology delivered nicotine with 90.2% greater delivery than the concentration-matched control formulation by the 10-minute mark and substantially greater absorption levels than the control formulation at all time intervals in the study. The company contracted a third-party laboratory to conduct the study which concentrated on detailed analysis of absorption over a 60-minute period. Lexaria's in vitro laboratory, in vivo…

Continue Reading